Loading...
MXCT logo

MaxCyte Community

AIM:MXCT Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

Community Investing Ideas

MXCT logo
MaxCyte

SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects

Key Takeaways Acquisition of SeQure Dx and SPL portfolio expansion could drive future revenue growth through improved offerings and new clinical progressions. Strategic focus on efficiency and high-growth areas may enhance net margins and long-term profitability amid expected market growth in cell and gene therapy.Read more

View narrative
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
UK£4.87
68.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
17.54% p.a.
Profit Margin
7.9%
Future PE
179.6x
Share price in 2028
UK£6.04